Holen Sie sich die Stockscreener-App
72.11
1.02%
0.73
Schlusskurs vom Vortag:
$71.38
Offen:
$71.66
24-Stunden-Volumen:
1.30M
Relative Volume:
0.72
Marktkapitalisierung:
$13.96B
Einnahmen:
$4.08B
Nettoeinkommen (Verlust:
$32.48M
KGV:
515.07
EPS:
0.14
Netto-Cashflow:
$16.80M
1W Leistung:
+2.40%
1M Leistung:
-1.85%
6M Leistung:
+12.41%
1J Leistung:
+19.53%
1-Tages-Spanne:
$71.50
$72.97
1-Wochen-Bereich:
$69.75
$72.97
52-Wochen-Spanne:
$50.35
$83.95
Incyte Corp Stock (INCY) Company Profile
Firmenname
Incyte Corp
Sektor
Branche
Telefon
(302) 498-6700
Adresse
1801 AUGUSTINE CUT-OFF, WILMINGTON, DE
Vergleichen Sie INCY mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
INCY
Incyte Corp
|
72.11 | 13.96B | 4.08B | 32.48M | 16.80M | 0.14 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.24 | 124.35B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
700.33 | 76.56B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
644.48 | 39.16B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
250.59 | 32.44B | 2.25B | -278.16M | -42.59M | -2.17 |
|
BNTX
Biontech Se Adr
|
120.01 | 28.77B | 3.30B | -501.07M | 1.03B | -2.1146 |
Incyte Corp Stock (INCY) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-12-17 | Eingeleitet | UBS | Neutral |
| 2024-10-29 | Hochstufung | BofA Securities | Neutral → Buy |
| 2024-10-01 | Eingeleitet | Wolfe Research | Outperform |
| 2024-09-18 | Herabstufung | Truist | Buy → Hold |
| 2024-07-02 | Herabstufung | BMO Capital Markets | Market Perform → Underperform |
| 2024-05-23 | Eingeleitet | Deutsche Bank | Hold |
| 2024-04-23 | Eingeleitet | Cantor Fitzgerald | Neutral |
| 2024-02-23 | Eingeleitet | Jefferies | Buy |
| 2024-02-14 | Herabstufung | JMP Securities | Mkt Outperform → Mkt Perform |
| 2023-12-13 | Hochstufung | Leerink Partners | Market Perform → Outperform |
| 2023-12-04 | Hochstufung | Guggenheim | Neutral → Buy |
| 2023-11-21 | Herabstufung | Goldman | Buy → Neutral |
| 2023-07-25 | Eingeleitet | Citigroup | Buy |
| 2023-05-04 | Herabstufung | BofA Securities | Buy → Neutral |
| 2023-04-10 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2023-03-24 | Hochstufung | SVB Securities | Underperform → Market Perform |
| 2023-01-31 | Eingeleitet | Piper Sandler | Overweight |
| 2022-08-03 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2022-08-03 | Herabstufung | Guggenheim | Buy → Neutral |
| 2022-07-28 | Eingeleitet | Wells Fargo | Equal Weight |
| 2022-02-09 | Herabstufung | SVB Leerink | Mkt Perform → Underperform |
| 2022-01-18 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2021-11-19 | Eingeleitet | BMO Capital Markets | Market Perform |
| 2021-07-20 | Hochstufung | The Benchmark Company | Hold → Buy |
| 2021-02-10 | Herabstufung | SVB Leerink | Mkt Perform → Underperform |
| 2021-01-07 | Eingeleitet | Truist | Buy |
| 2021-01-04 | Hochstufung | Guggenheim | Neutral → Buy |
| 2020-06-16 | Eingeleitet | The Benchmark Company | Hold |
| 2020-05-06 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2020-04-29 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2020-04-01 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2020-03-24 | Fortgesetzt | William Blair | Outperform |
| 2020-03-13 | Hochstufung | BofA/Merrill | Neutral → Buy |
| 2020-02-04 | Fortgesetzt | BofA/Merrill | Neutral |
| 2020-01-03 | Bestätigt | BMO Capital Markets | Market Perform |
| 2020-01-03 | Herabstufung | Mizuho | Buy → Neutral |
| 2020-01-02 | Herabstufung | Guggenheim | Buy → Neutral |
| 2019-10-03 | Eingeleitet | Mizuho | Buy |
| 2019-09-12 | Eingeleitet | BMO Capital Markets | Market Perform |
| 2019-09-05 | Hochstufung | JMP Securities | Mkt Perform → Mkt Outperform |
| 2019-09-05 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2019-09-05 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2019-05-21 | Eingeleitet | Credit Suisse | Neutral |
| 2019-05-03 | Herabstufung | Barclays | Overweight → Equal Weight |
| 2019-04-11 | Eingeleitet | Stifel | Hold |
| 2019-04-03 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2019-01-24 | Hochstufung | William Blair | Mkt Perform → Outperform |
Alle ansehen
Incyte Corp Aktie (INCY) Neueste Nachrichten
Lobbying Update: $350,000 of INCYTE CORPORATION lobbying was just disclosed - Nasdaq
Incyte Corp. partners with Genesis Therapeutics to use AI for drug discovery - The Business Journals
Incyte and Genesis go boldly into AI-focused research - The Pharma Letter
Incyte joins the group getting guidance from AI’s Genesis - BioWorld Online
Incyte Secures Exclusive Rights In $30Mln AI Collaboration With Genesis Therapeutics - Nasdaq
Incyte partners with Genesis to discover new small molecule drugs - Investing.com
AI Meets Drug Discovery: Inside Incyte's $620M Genesis DealWill This Transform Pharma R&D? - StockTitan
Incyte to Present at Upcoming March 2025 Investor Conferences - BioSpace
Exclusive Healthcare Investor Access: Incyte's Double Conference Reveal Coming in March - StockTitan
Are Wall Street Analysts Bullish On Incyte Stock? - Barchart
Incyte's SWOT analysis: stock prospects amid patent cliff and pipeline potential - Investing.com
Are Wall Street Analysts Bullish on Incyte Stock? - Nasdaq
Incyte corp EVP Steven Stein sells shares worth $897,866 - MSN
Incyte jumps amid takeover speculation - MSN
INCY's Q4 Earnings Miss Mark, Revenues Beat on Higher Product Sales - MSN
Incyte (NASDAQ:INCY) Stock Rating Lowered by StockNews.com - MarketBeat
Incyte (NASDAQ:INCY) Price Target Raised to $77.00 at Stifel Nicolaus - MarketBeat
Incyte outlines 2025 milestones with projected $1B in incremental revenue contributions - MSN
abrdn plc Cuts Position in Incyte Co. (NASDAQ:INCY) - MarketBeat
Incyte (NASDAQ:INCY) Trading Down 8.5% Following Weak Earnings - MarketBeat
State of Alaska Department of Revenue Has $1.26 Million Stake in Incyte Co. (NASDAQ:INCY) - MarketBeat
Citigroup Issues Pessimistic Forecast for Incyte (NASDAQ:INCY) Stock Price - MarketBeat
Stifel raises Incyte stock price target to $77 from $75 - MSN
Sumitomo Mitsui Trust Group Inc. Cuts Stock Position in Incyte Co. (NASDAQ:INCY) - MarketBeat
Incyte (NASDAQ:INCY) Issues Earnings Results - MarketBeat
Incyte stock falls 6% amid Q4 earnings, 2025 forecast - MSN
Incyte stock price target raised to $88 at TD Cowen - MSN
Cambiar Investors LLC Has $9.65 Million Holdings in Incyte Co. (NASDAQ:INCY) - MarketBeat
JPMorgan Adjusts Incyte Price Target to $70 From $75, Maintains Neutral Rating -February 12, 2025 at 10:29 am EST - Marketscreener.com
Incyte backs out of immuno-oncology pact with Agenus - PharmaLive
Reevaluating Incyte Corporation After Earnings (Technical Analysis) - Seeking Alpha
Incyte Backs Out of Immuno-Oncology Pact With Agenus - BioSpace
Decoding Incyte Corp (INCY): A Strategic SWOT Insight - GuruFocus.com
Incyte Earnings: Strong Opzelura Sales; Focus on Expanding Portfolio Amid Jakafi Patent Expiration - Morningstar
Upcoming Patent Loss of Jakafi Highlights Portfolio Risks; Downgrading Incyte's Moat to None - Morningstar
Incyte's Revenue Beats Estimates Thanks To Jakafi And Opzelura - Finimize
Curious about Incyte (INCY) Q4 Performance? Explore Wall Street Estimates for Key Metrics - MSN
Incyte (INCY) Stock Drops Amid Slower Growth Outlook - GuruFocus.com
Royal Bank of Canada Has Lowered Expectations for Incyte (NASDAQ:INCY) Stock Price - MarketBeat
RBC cuts Incyte stock price target to $68 from $70 - Investing.com
Incyte Corporation (NASDAQ:INCY) Q4 2024 Earnings Call Transcript - Insider Monkey
What Analysts Are Saying About Incyte Stock - Benzinga
Citi cuts Incyte stock price target to $88, maintains buy rating - MSN
Jefferies Adjusts Price Target on Incyte to $81 From $84, Maintains Buy Rating -February 11, 2025 at 07:18 am EST - Marketscreener.com
Incyte Full Year 2024 Earnings: Revenues Beat Expectations, EPS Lags - Yahoo Finance
Incyte’s Strong 2024 Financial Performance and Promising Outlook - MSN
Applovin, Incyte, Onsemi - TradingView
Incyte Corp (INCY) Q4 2024 Earnings Call Highlights: Strong Revenue Growth and Strategic Outlook - Yahoo Finance
Incyte Corp (INCY) Q4 2024 Earnings Call Highlights: Strong Revenue Growth and Strategic Outlook By GuruFocus - Investing.com Canada
Why Incyte (INCY) Shares Are Plunging Today - The Globe and Mail
Incyte (INCY) Reports Q4 Earnings: What Key Metrics Have to Say - MSN
Finanzdaten der Incyte Corp-Aktie (INCY)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.27%
3.05%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):